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BasiC sCienCe
introduCtion
Although the mechanisms underlying PC evolution still remain 
poorly understood, a positive correlation between PC progression, 
loss of function of PTEN, and phosphorylation of Akt (pAkt) has 
been reported by a number of studies [1-3]. Akt is a protein kinase 
activated by various growth and survival factors and involves PI3-
kinase (PI3K) [4], a well-established dominant survival mechanism 
in a wide spectrum of human cancers. In addition to PI3-K, Akt 
activity can be controlled via various phosphatases including PTEN. 
In particular, in PC, PTEN is thus far the most frequently mutated 
tumor suppressor gene [5, 6] where deletions, point mutations, and 
DNA methylation are reported to occur  in almost 50% of hormone 
refractory tumors [7]. 
Progression of androgen-independent PC (AIPC, also called 
castrate or hormone resistant PC – HRPC) has also been associ-
ated with functional up-regulation of the Bcl-2 protein [8].  A 
number of reports, including our own work [9], demonstrated a 
link between Bcl-2 over-expression and PC radio- and chemo-
resistance. In LNCaP  cells, over-expression of Bcl-2 inhibited 
apoptosis induced by PTEN suggesting an association between 
the PI3K/Akt/PTEN signaling and Bcl-2 in the survival mechanism 
of PC cells [10]. 
Doxazosin, a selective α−1 adrenoceptor antagonist widely 
used in the management of benign prostatic hyperplasia (BPH), has 
been reported to induce apoptosis in PC cells. Investigations uti-
lizing both androgen-sensitive and -insensitive PC cell lines have 
shown that the pro-apoptotic action of doxazosin is independent 
of α1-adrenoceptor action and appears to be independent of the 
androgen sensitivity of the cells [11]. The underlying mechanism 
involves activation of the TGF-β1-mediated signaling, but other 
pathways have also been implicated [12-14].  In particular, Shaw et 
al. have recently demonstrated that doxazosin–induced apoptosis 
of PC-3 cells carrying a mutated PTEN  was, in part, attributable to 
the inhibition of Akt activation [15].  
As an impact of interactions between the androgen receptor 
(AR) and PTEN–Akt signaling axes on PC progression has been well 
documented [16, 17], our study  aimed to assess the effects of 
doxazosin on the growth of PC cells with a functional AR and PI3K/
Akt/PTEN pathway.  We used the DU145-derived in vitro model to 
examine a potential association between the apoptotic effect of 
doxazosin and Akt activation in relation to PC cell androgen sensi-
tivity and Bcl-2 expression.
Materials and Methods
reagents and antibodies
Doxazosin mesylate (dox)  (Cardura) was kindly donated by 
Pfizer Ltd. (Sandwich, UK). Epidermal growth factor (EGF) and the 
MTT assay were purchased from Promega (UK) and dihydrotes-
tosterone (DHT) from Sigma (UK). Rabbit anti-Akt and anti-pAkt 
(Ser473) were obtained from Cell Signaling (UK); mouse anti-AR 
from Biogenex (UK); mouse anti–PTEN from Neomarkers (USA); 
anti-mouse IgG Alexa Fluor from Invitrogen (UK) and horse biotin-
conjugated anti-mouse IgG from Vector Labs (UK).  
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aBstraCt
introduction.  Doxazosin, a selective α1-adrenoreceptor 
antagonist widely used in the management of benign 
prostatic hyperplasia (BPH), has been shown to induce 
apoptosis in androgen-independent (AI) and PTEN (phos-
phatases and tensin homolog)-negative prostate cancer 
(PC) cells. The objective of this study was to assess the 
effects of doxazosin on the growth of PC cells with a 
functional PTEN/PI3K/Akt pathway in relation to cell 
androgen sensitivity and Bcl-2 expression.
Material and methods. The DU145 cell line and two 
derivatives: 1) DKC9 [DU145 (Bcl2 +/+)] and 2) DAR19 
[DU145 (AR+/+)] were used. The effect of doxazosin 
on i) cell proliferation and ii) Akt phosphorylation was 
measured using the MTT assay and Western blotting, 
respectively. 
results.  Doxazosin caused significant concentra-
tion, but not time-dependent, decrease in cell viability. 
The threshold of sensitivity to the compound differed 
between the cell lines and was the lowest in the parental 
cell line. In DAR 19 cells, AR-mediated signaling further 
increased cell resistance to doxazosin. In all cell lines, 
doxazosin-induced apoptosis was rescued by EGF stimu-
lation and, in DAR19 cells, by AR activation. Doxazosin 
reduced basal and EGF-/DHT-induced Akt phosphoryla-
tion.  
Conclusions. This study demonstrates that doxazosin 
induces apoptosis in PTEN-positive AI PC cells, at least 
partially, via Akt deactivation and that over-expression 
of Bcl-2 or AR increases cell resistance to the drug. 
These results imply that translational potential of dox-
azosin depends on phenotypic characteristics of PC cells 
and provide evidence for limitations to its application in 
hormone refractory tumors.
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Cell lines
DU145, a human prostate adenocarcinoma cell line (ATCC, 
Rockville, MD), was grown in Dulbecco’s Modified Eagles Medium 
(DMEM; Sigma-Aldrich, UK) containing 10% Fetal Bovine Serum 
(FBS) (Invitrogen, UK), 2 mM L-glutamine, and 1% Pen-Strep-
Amphotericin solution  (Gibco Life  Technologies, U.K); further 
referred to as complete DMEM. Cells grown at 37°C and 10% Co2 
were routinely sub-cultured at a 1:3 ratio and re-fed daily with 
fresh medium. 
Two stably transfected cell lines: 1) DKC9 (DU145 Bcl2 +/+) and 
2) DAR19 (DU145 AR +/+) developed from the parental DU145 cell 
line [9, 18] were used in the study. Cells were grown in complete 
DMEM; the medium for i) DKC9 was supplemented with Puromycin 
(0.5 µg/ml; Sigma-Aldrich, UK) and ii) DAR19 with Zeocin (300 µg/
ml; Invitrogen, UK).
proliferation assay
Cells seeded into a 96-well plate (104 cells/well) were grown 
in complete DMEM for 24 hours. The medium was replaced with 
serum-free medium (SF-DMEM) and the cells were cultured for 
the next 24 hours. Doxazosin was then applied at ascending con-
centrations ranging from 10 µM to75 µM (day 0). To examine the 
effects of doxazosin on DHT-  or EGF-stimulated cell proliferation, 
on day 0 the medium was replaced with fresh SF-DMEM contain-
ing EGF (50 ng/ml) [19] or DHT (5 nM) [18] alone or in combination 
with doxazosin (10-75 µM). The medium was refreshed every 24 
hrs. Untreated cells (0 µMdox) were used as a control. Cell num-
bers were assessed  for i) treatment with  dox +/- DHT after  1, 
2, 3, 4, and 5 days and ii) dox +/- EGF after 3 days of incubation 
using an MTT Assay, according to the  manufacturer’s instructions. 
Numerical data represent the average of three independent experi-
ments performed in quintuplicate. Values were standardized to 
that of the control (100%) and presented as mean ± SEM.
akt phosphorylation assay 
Cells were grown to confluency in complete DMEM. The 
medium was then replaced with fresh SF-DMEM and cells were 
grown for the next 24 hours. Cells were treated with i) dox (50 
µM; 24 hours) and ii), EGF (50 ng/ml; 20 min prior to harvesting), 
or iii) DHT (5 nM; 30 min prior to harvesting) alone or in combina-
tion. Cells were harvested and lysed at the end of the designated 
incubation time.
western Blotting
Cells were lysed with cold cell lysis buffer [20 mM Tris-HCl, 
pH7.5, 150 mM NaCl, 1 mM Na2EDTA. 1 mM EGTA, 1% (v/v) Triton, 
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3Vo4, 1 µg/ml leupeptin, 1 mM PMSF (Cell Signaling, Hitchin, 
Fig. 1. Effect of doxazosin on growth of: A) -C)  unstimulated cells: A) DU145; B) DKC9; and C) DAR19. Cells were seeded at a density of 104 cells/well into a 96-well 
plate and left to grow in complete DMEM for 24 hours.  They were rendered quiescent by incubation with SF-DMEM for 24 hours and then treated in the absence 
of serum with doxazosin in ascending concentrations ranging from 10 µM to 75 µM.  D) DAR19 cells stimulated with DHT.  Cells were treated as above and on day 0 
the medium was replaced with fresh SF-DMEM containing DHT (5nM) alone (untreated 0 µM dox control) or in combination with ascending concentrations (10-75 
µM) of doxazosin. For all A) – D), cell numbers were determined prior to treatment (Day 0) and after 1, 2, 3, 4, and 5 days of incubation by a MTT Assay (Promega, UK). 
Data expressed as the average of at least three individual experiments are presented as percentage of Day 0 (control). A value of p <0.05 was considered to be sta-
tistically significant (statistical significance: * P <0.05, **  P <0.01, and *** P <0.001). For each cell line and concentration of doxazosin, the figures represent average 
values of data collected on consecutive days of treatment.  
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UK)] for 5 minutes on ice, then scraped and sonicated. Equal 
amounts of lysate proteins (30 µg) resolved by 10% SDS-PAGE, 
were transferred to a nitrocellulose membrane and probed with 
rabbit anti-Akt (1:1000) and rabbit anti-pAkt (ser 473) (1:1000). 
Membranes incubated with HRP (horseradish peroxidase)-conju-
gated anti-rabbit antibodies (HRP; 1:5000, GE Healthcare UK) were 
visualized by enhanced chemiluminescence (Amersham Bioscience, 
USA). Blots were developed using the automatic Kodak film devel-
oper system (Kodak, UK).
immunocytochemistry 
immunofluorescence for ar
Cells grown on chamber slides in DMEM supplemented with 
10% charcoal stripped fetal bovine serum (csFBS; Invitrogen, 
UK) were stimulated with DHT (30 min; 5 nM) then fixed in 
methanol:acetone (1:1 v/v; -20°C) and immunostained for AR 
(1:10). 
immunocytochemistry for pten
Cells grown on chamber slides in complete DMEM were fixed 
in 4% paraformaldehyde and immunostained for PTEN.  The 
anti-PTEN monoclonal antibody recognizes an epitope at the 
C-terminus of PTEN, which is lost in a range of human tumors 
[20]. Images were captured using a digital camera system (Nikon 
E400, japan).  
statistical analysis
The statistical analysis was done using Prism software. one-way 
ANoVA (analysis of variance) and Dunnet’s test were performed. A 
value of p <0.05 was considered to be statistically significant (sta-
tistical significance: * P <0.05, ** P <0.01, and *** P <0.001). 
results
i. effects of doxazosin on growth of prostate Cancer cells
DU145 (the parental cell line) and its two derivatives: 1) DKC9 
[DU145 (Bcl2 +/+)]  and 2) DAR19 [DU145 (AR+/+)] were grown 
in SF-DMEM and treated with doxazosin in ascending concentra-
tions of 10, 25, 50, and 75 µM, equivalent to those previously 
reported [21], for 24-120 hours. In all cell lines, doxazosin caused 
cell death and this effect was concentration-dependent (Fig. 1). 
The threshold of sensitivity to the compound differed between 
the cell lines (Fig. 1) and was the lowest in the parental cell line. 
In DU145 cells, decrease in cell viability was up to 41.5 ±6.23 % 
(P <0.01), 11.8 ± 8.75 % (P <0.001), and 4.00 ±1.09 % for 25 µM, 
50 µM, and 75 µM respectively. The proportion of viable DKC9 
cells treated with 50 µM and 75 µM was 63.99 ±9.63% (P <0.05) 
and 9.96 ±3.79% (P <0.001), respectively. DAR19 cells were also 
more resistant to the drug than control cells. Doxazosin caused a 
decrease in their viability at 50 µM and 75 µM to 28.93 ±9.641% 
(P <0.01) and 4.94 ±1.02% (P <0.001), respectively (Fig. 1). Longer 
incubation with the compound did not have any significant effect 
on cell growth (Fig. 1). These results suggest that both over-ex-
pression of Bcl-2 and restoration of androgen sensitivity increase 
resistance of the cells to the apoptotic activity of doxazosin. 
In order to assess whether ligand-induced activation of AR can 
enhance this protective effect, DAR19 cells treated with doxazosin 
were stimulated with 5nM DHT.  The conditions of DHT treatment 
(concentration and duration) were previously optimized and shown 
to induce translocation of AR to the nucleus in DAR19 cells within 
30 min (Fig. 2) [18].
As illustrated in Figure 1D, incubation of DAR19 cells with DHT 
raised the threshold of cell sensitivity to doxazosin; at concentra-
fig. 2. AR expression in DAR19 cells.  A) Immunocytochemistry: In the absence of DHT, AR expression is localized mainly to the cytoplasm. Treatment with 5 nM 
DHT results in the translocation of AR to the nucleus within 30 min.  Nuclei stained with DAPI. B)  Immunoblotting. A single 110 kD AR reactive band was observed 
in both lanes. Addition of 5nM DHT to the culture medium did not alter total AR protein content.
fig. 3. A) Expression of PTEN in DU145 cells. PTEN expression is confined to the cytoplasm. All cells express PTEN, but the intensity of staining is heterogeneous. 
B) EGF – mediated pAkt phosphorylation. Parental DU145 cells and 2 derivatives DKC9 and DAR19 cells serum starved for 24 hours were treated with 50 ng/ml EGF for 
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tions of 50 µM and 75 µM, cell growth was rescued to 53.57 
±5.08% (P <0.01) and  43.84  ±5.82%  (p <0.001), respectively. 
These results indicate that proliferation induced by AR-mediated 
signaling counteracts the apoptotic activity of doxazosin on andro-
gen-sensitive PC cells. This protective effect was more pronounced 
than that seen in unstimulated Bcl-2-expressing PC cells. 
As expected, DHT did not affect proliferation of neither DU145 
nor DKC9 cells (not shown). 
effect of doxazosin on akt-mediated signaling in pC cells
DU145 is a PTEN positive cell line, expressing low basal level of 
activated Akt [22].  These cells also express EGFR [19] and stimulation 
with EGF (50 ng/ml) induces Akt phosphorylation (Fig. 3). Continuous 
EGF stimulation evokes a proliferative response of DU145 cells that 
reaches its maximum after 72 hours of stimulation [19]. 
a) effects on egf-induced pC cell proliferation 
To examine a potential association between the apoptotic 
effect of doxazosin and growth promoting Akt activation, cells 
stimulated with EGF (50ng/ml) were treated with ascending con-
centrations of doxazosin (10 µM, 25 µM, 50 µM, and 75 µM). Cell 
proliferation was assessed in triplicate cultures after 72 hours of 
treatment [19].  
Incubation with EGF attenuated the pro-apoptotic activity 
of doxazosin in all cell lines.  At 50 µM and 75 µM of doxazosin, 
cell growth was rescued to A) 56.57 ±1.58% (P <0.01) and 
22.41  ±2.13%  (p <0.001), B) 112.5 ±2.43% (P >0.05) and 42.61 
±2.03% (P <0.01), and C) 87.84 ±5.16% (P >0.05) and  22.37 
±6.01% (P <0.01)  in DU145, DKC9, and DAR19 cells respectively 
(Fig. 4). 
B. effects of doxazosin on akt phosphorylation 
To further investigate the mechanisms underlying the pro-
apoptotic activity of doxazosin, cells were treated with EGF and 
doxazosin alone and in combination. Concentration and duration 
of doxazosin applications (50 µM for 24 hours) were chosen on 
the basis of results of the proliferation assays described above (all 
cell lines exhibited a significant decrease in cell viability – Fig. 1). 
As shown in Figure 5, doxazosin caused a decrease (~2 fold) in the 
levels of both basal and EGF-induced pAkt in all cells. This sug-
gests that 1) the inhibitory effect of doxazosin on PC cell growth 
can be attributable (at least partially) to deactivation of Akt and 2) 
over-expression of Bcl-2 or AR significantly reduces this effect and 
increases resistance of androgen independent human PC cells to 
this compound.
C. effects of doxazosin on dht-induced akt phosphorylation 
A crosstalk between the PTEN/Akt pathway and AR-mediated 
signaling in PC cells has been well documented [23-25]. Androgens 
have been shown to activate the PI3K/Akt signaling pathway in 
fig. 4. Effects of doxazosin on growth of EGF-stimulated cells: A) DU145, B) DKC9, C) DAR19. Cells were seeded at a density of 104 cells/well into a 96-well plate 
and left to grow in complete DMEM for 24 hours.  They were rendered quiescent by incubation with SF-DMEM for 24 hours and then treated with fresh  
SF- DMEM containing i) EGF (50 ng/ml) alone or in combination with doxazosin at concentrations of 10-75 µM (continuous line) or ii) doxazosin in concentrations 
of 10-75 µM (dotted line). Cell growth was assessed after 3 days of treatment by MTT assay.  D) Combined growth curves of all 3 cell lines. Data expressed as the 
average of at least three individual experiments are presented as percentage of control (0 µM dox) values. P <0.05 was considered to be statistically significant 
(statistical significance: * P <0.05, ** P <0.01, and *** P <0.001).  
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PC-3 cells only once they have been transfected with AR [26]. We 
have confirmed this observation and shown that DHT induced 
Akt activation in DAR19, but not in the parental DU145 cells (Fig. 
6A). In order to examine whether activation of Akt contributes to 
the mechanisms underlying AR-mediated resistance of PC cells to 
doxazosin, DAR19 cells treated with doxazosin were stimulated 
with DHT (5 nM, 30 min) and expression of pAkt was assessed by 
Western blotting. The results show that doxazosin decreased DHT-
induced expression of pAkt (Fig. 6B). 
disCussion
Several previous reports have associated the pro-apoptotic 
action of doxazosin with various PC cell phenotype characteristics. 
However, due to the heterogeneity of tumors and variability in PC 
progression, an accurate prediction of response to therapy calls for 
in vitro models with a wide spectrum of PC cell phenotypes. In this 
report, three isogenic PC cell lines were used for the first time to 
assess the effect and action of doxazosin on a PTEN-positive and 
androgen-sensitive PC cells.  
Consistent with previous reports, doxazosin induced inhibition 
of PC cell growth. In all cell lines, this effect was concentration-de-
pendant and reached plateau within the first 24 hrs of application. 
Longer incubation with the drug did not have any further effect on 
cell viability. In a recent study, Cal et al., used DU145 cells to dem-
onstrate that doxazosin-induced apoptosis was time-dependent, 
peaking within 72 hours of application [27]. The discrepancies 
between these observations and our findings are likely to be due 
to the differences in the experimental conditions. Unlike Cal et 
al., our experiments were carried out under conditions of serum 
starvation thus allowing the drug to reach much faster intracel-
lular saturation levels. Indeed, doxazosin has been shown to have 
a high affinity to serum proteins and, hence, has a lower potency 
in a serum-rich environment [28].    
The threshold of cell sensitivity to the compound differed 
between the cell lines with the lowest being in the parental, 
AR-negative, and Bcl-2-negative cells. Restoration of androgen 
sensitivity increased resistance to doxazosin and this was further 
enhanced by activation of AR-mediated signaling. This suggests 
that an ability to activate survival mechanisms makes PC cells more 
resistant to external apoptotic stimuli activated by doxazosin. In 
contrast to our observation, Benning et al., have previously report-
ed that the apoptotic activity of doxazosin is independent of the 
hormone sensitivity status of the cells [11]. Their study, however, 
was carried out in a PTEN–deficient LNCaP cell line. A strong link 
between AR–induced signaling and the PTEN–Akt axis in PC have 
been documented by a number of reports [16, 29]. For example, Akt 
is known to regulate the stability of the AR and acts synergistically 
with both AR-nuclear and nongenotropic signaling [30]. PTEN, on 
the other hand, has antagonistic interactions with AR by repress-
ing the transcriptional activity of AR through the inhibition of Akt 
phosphorylation. Interestingly, ligand-activated AR protects PC 
cells from PTEN-induced apoptosis in an Akt-independent man-
ner, thereby suggesting that the interaction between the AR- and 
PTEN-dependent signaling networks is even more complex [31]. 
These reciprocal interaction loops are modified and finely tuned 
by the hormonal status of the cell. Neither the role of PTEN nor 
its impact on the responsiveness of  androgen-independent PC to 
therapy is fully understood. Little is also known about the interac-
tions of doxazosin with pathways mediated by ligand activation 
of steroid receptors in hormone–regulated cancers in general. Hui 
at al. have recently demonstrated that in ER- and PTEN-positive 
breast cancer cells, doxazosin-induced apoptosis was less marked 
in the presence of estrogen [32]. Together with our results, these 
data would suggest that, in hormone-dependent and/or sensitive 
cancers, a cross-talk between various intracellular mechanisms, 
including the PI3K/Akt/PTEN and hormone receptors-mediated 
pathways, may decide on the ultimate responsiveness of tumor 
cells to the drug. 
fig. 5. Effects of doxazosin on EGF-stimulated Akt phosphorylation in DU145, 
DKC9, and DAR19 cells. Cells serum-starved for 24 hours were treated with dox 
(50 µM; 24 hours) and/or EGF (50 ng/ml; 20 min prior to harvesting). Blots were 
probed with antibodies to pAkt and Akt.
fig. 6. A) DHT- mediated Akt phosphorylation DAR19 and parental DU145 cells serum-starved for 24 hours were treated with 5nM DHT for 0, 15, 30, and 60 min. 
Immunoblots probed with specific antibodies against pAkt (Ser473) and total Akt show an increase in Akt phosphorylation only in DAR19 cells. B) Effects of doxa-
zosin on DHT-stimulated Akt phosphorylation in DAR19 cells. Cells serum-starved for 24 hours were treated with dox (50 µM; 24 hours) and/or DHT (5 nM; 30 min 
prior to harvesting). Blots were probed with antibodies to pAkt and Akt.
A) B)
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There is increasing evidence to suggest that doxazosin executes 
its action by affecting multiple intracellular signaling mechanisms 
[11-15, 33]. our results showed that activation of EGFR-mediated 
signaling partially rescued all cell lines from doxazosin-induced 
apoptosis with a gradient of sensitivity similar to that seen in 
unstimulated cells.  In addition, in all cell lines, doxazosin decreased 
EGF-induced Akt activation. The reduction of Akt phosphoryla-
tion by the drug has already been reported in PC-3 cells [15]. 
The authors demonstrated that although doxazosin inhibited Akt 
phosphorylation in these cells (androgen-independent and insensi-
tive as well as PTEN-negative), it did not have any direct effects on 
the activity of any of the known kinases upstream of Akt, includ-
ing PI3K. Since the compound did not affect the phosphorylation 
status of ERK (extracellular signal-regulated kinase), it has been 
suggested that its action might be specific to intracellular path-
ways interfering with other alternative intracellular Akt targeting 
mechanisms such as competition for ATP-binding or the death-
receptor pathway [15]. It is also possible that this inhibitory effect 
is due to the substrate-specific phosphatase activity of doxazosin 
[34].  Whatever the exact mechanisms, our results together with 
the above findings indicate that Akt is one of the downstream tar-
gets and inhibition of its phosphorylation is likely to contribute to 
the final biological effect of doxazosin. In their recent study, Hui et 
al. demonstrated that doxazosin-induced apoptosis in a hormone-
independent PTEN–positive MDA-MB-231 breast cancer cell line 
partially via the reduction of ERK phosphorylation [32]. While 
seemingly conflicting with reported data on PC-3 cells [15], these 
findings might suggest that the mechanism of doxazosin action is 
dependent on PTEN / hormonal status of the cells. 
Bcl-2 has been shown to carry out survival functions against 
a range of apoptotic stimuli in a variety of cell systems. In PC, the 
de novo expression of Bcl-2 has been associated with progres-
sion to androgen-independence and up-regulation of this protein 
was often found in hormone refractory tumors [8]. Although the 
molecular mechanisms underlying the death suppressing activity 
of Bcl-2 in cancer cells are not fully understood, in vitro stud-
ies have consistently reported a link between the anti-apoptotic 
potential and cytotoxic chemoresistance of Bcl-2-expressing 
tumor cells [9, 35-37].  Furthermore, it has been recently demon-
strated that Bcl-2 and doxazosin produced opposing effects on 
PC cell survival [14]. our results confirm these observations and 
show that enforced expression of Bcl-2 partially rescues the cells 
from doxazosin-induced apoptosis but does not block the inhibi-
tory effect of doxazosin on Akt phosphorylation. These data are 
consistent with previous studies and give support to the notion of 
a multifaceted antitumor effect of doxazosin that targets several 
cell survival pathways.  
In summary, the results of our study show for the first time 
that the pro-apoptotic effect of doxazosin on PC cells is modu-
lated by the hormonal status of the cells. Doxazosin is believed 
to hold a great promise for both the treatment and prevention 
of PC [38, 39], but its exact interactions with molecular mecha-
nisms governing the intricate process that defines the balance 
between cell proliferation and death and, in particular, the func-
tional PTEN/AR relationship are still not understood. our findings, 
together with those already published, imply that a translational 
potential for doxazosin in PC depends on the phenotypic charac-
teristics of the tumor and should be viewed as such to guide the 
selection of patients for specific therapeutic strategies.
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